Compare NWL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWL | TRVI |
|---|---|---|
| Founded | 1903 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1995 | 2019 |
| Metric | NWL | TRVI |
|---|---|---|
| Price | $4.91 | $14.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $4.97 | ★ $21.55 |
| AVG Volume (30 Days) | ★ 9.0M | 916.5K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,742,200,000.00 | N/A |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.14 | N/A |
| 52 Week Low | $3.07 | $5.41 |
| 52 Week High | $6.64 | $16.12 |
| Indicator | NWL | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 71.75 | 56.04 |
| Support Level | $4.83 | $10.07 |
| Resistance Level | $5.14 | $14.57 |
| Average True Range (ATR) | 0.28 | 0.58 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 94.72 | 80.34 |
Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.